Currently, multiple small-molecule inhibitors of PARP, including olaparib, rucaparib, niraparib and talazoparib, have been approved by the FDA with indications for the treatment of breast (olaparib, talazoparib), ovarian (olaparib, rucaparib, niraparib), prostate (olaparib, rucaparib) and pancreatic cancer (olaparib) [48]. Here, PARP1 is linked to pancreatic neoplasm.